Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 2100505 | [Arthroscopic synovectomy of the shoulder and elbow joint]. | 1990 Nov | We reviewed experiences and results of six shoulder and nine elbow joint synovectomies, performed in a time period between 1989 and 1990 by arthroscopic technique. The operation technique is pretentious an requires some expenditure. The postoperative course distinguishes itself by little pain and early increase of range of motion. | |
| 3580283 | The origin of the apparent synovial lining cell hyperplasia in rheumatoid arthritis: evide | 1987 Apr | The experimental model of inflammatory arthritis in the rabbit has been used to study the possible origin of the apparent synovial lining cell hyperplasia. A small amount of 3H-thymidine was injected into the joints and the fate of the labelled cells investigated by autoradiography. At times up to 24 h after the injection, most of the labelled cells occurred in the sub-lining region; this proportionality was reversed when the joints were sampled at later times. These results indicate that at least much of the increase of synovial lining cells may be derived from cells from deeper in the synovial tissue which move to the synovial surface. | |
| 3751351 | [Pneumonia in cyclosporin A-treated chronic polyarthritis (a case report)]. | 1986 May | A 71 year old patient with seropositive rheumatoid arthritis developed rapidly progressive pneumonitis with bilateral pulmonary infiltrations and severe hypoxemia. At this time the patient was treated with cyclosporin A, indomethacin, chlorthalidone, amitriptyline and chlordiazepoxide. After these medicaments were discontinued and prednisone therapy was initiated a rapid remission of the pneumopathy was observed. It is probable that the reversible pneumopathy was induced by the treatment with cyclosporin A. Among the other medicaments which were stopped at the same time as cyclosporin A no comparable side effects are known. | |
| 2692412 | Presence of immunoreactive tissue kallikrein in human polymorphonuclear (PMN) leucocytes. | 1989 | The presence of tissue kallikrein in polymorphonuclear (PMN) leucocytes from normal human blood and from patients with rheumatoid arthritis and pyelonephritis was investigated. Immunoreactive tissue kallikrein was specifically detected in neutrophil leucocytes. PMN leucocytes displayed a granular staining. In the synovial membrane and kidney, the cells were aggregated into pockets as part of an inflammatory infiltrate. The presence of immunoreactive tissue kallikrein in human PMN leucocytes may provide a new insight into the importance of this enzyme in inflammation. | |
| 3052052 | New perspectives on the pathogenesis of rheumatoid arthritis. | 1988 Oct 14 | In the pathogenesis of rheumatoid arthritis, locally produced antibodies complex with an inciting antigen, yet to be identified, within the joint and activate the complement system, resulting in articular inflammation mediated primarily by polymorphonuclear leukocytes and their products. Chronic inflammatory cells then produce soluble factors that induce both tissue destruction and inflammation. A major issue is how and why apparently normal immune responses in the acute stage progress to chronic inflammation in subsequent months to years. Although it is often assumed that the initial etiologic agent, persisting in the joint or at an extra-articular site, is responsible for continued synovitis, this need not be the case. It is possible that once the inciting agent is cleared from the joint through a normal immune response, the presence of activated cells rich in surface class II histocompatibility (Ia) antigens could, under the influence of multiple genetic or environmental factors, become the target of autoimmune attack. Alternatively, the process might result from the interactions of synovial lining cells and their products with T cells assuming a secondary role. Further research into the relative contributions of soluble products, T helper and suppressor subsets, synoviocytes, and antigen determine which model is correct. | |
| 3731715 | Lung function abnormalities in different connective tissue diseases. | 1986 Jun | Lung volumes, forced expiratory flow-volume curves, diffusing capacity indexes, and arterial blood gases were measured in 72 non-smoking patients with various connective tissue diseases (13 with rheumatoid arthritis, 17 with systemic lupus erythematosus, 25 with progressive systemic sclerosis, 10 with primary Sjögren's syndrome, 4 with polymyositis, and 3 with mixed connective tissue disease). Small airways disease and a diffusion capacity impairment were the most frequent and marked functional abnormalities in the whole group, and were often present in asymptomatic patients. Different lung function defects seemed to be present in each disease group. In fact, large airway obstruction was prevalent in progressive systemic sclerosis, diffusion capacity impairment in systemic lupus erythematosus, and small airways disease in rheumatoid arthritis. In contrast, primary Sjögren's syndrome appeared to be the connective tissue disease in which lung function abnormalities were less frequent and less pronounced. | |
| 2433770 | Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthr | 1987 Feb 20 | Several clinical features are consistent with nervous system involvement in the pathogenesis of rheumatoid arthritis. The neuropeptide substance P is one possible mediator of this interaction, since it can be released into joint tissues from primary sensory nerve fibers. The potential effects of the peptide on rheumatoid synoviocytes were examined. The results show that substance P stimulates prostaglandin E2 and collagenase release from synoviocytes. Furthermore, synoviocyte proliferation was increased in the presence of the neuropeptide. Similar effects were observed with a truncated form of substance P. Synoviocytes were sensitive to very small doses of the neuropeptide (10(-9) M), and its effects were inhibited by a specific antagonist. Thus, the specific stimulation of synoviocytes by the neuropeptide substance P represents a pathway by which the nervous system might be directly involved in the pathogenesis of rheumatoid arthritis. | |
| 2619150 | An unusual case of painful ophthalmoplegia in a patient with rheumatoid arthritis. | 1989 Nov | A 43-year-old woman with long-standing rheumatoid arthritis and systemic lupus erythematosus had pain and horizontal diplopia. Clinical symptoms were consistent with inflammation of the right superior oblique tendon sheath, but a computed tomographic scan showed no pathology. Treatment with systemic corticosteroids reduced the symptoms, but the patient was left with a persistent muscle imbalance. | |
| 2181021 | Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An | 1990 Feb 20 | A 1 h, one-step sandwich enzyme immunoassay was set up with a pair of monoclonal antibodies prepared against bovine tissue inhibitor of metalloproteinases (TIMP). TIMP in samples was allowed to react simultaneously with both solid-phase antibody and peroxidase-labeled Fab' of another antibody. Minimum sensitivity was 1 pg/well for bovine TIMP and 1.5 pg/well for human TIMP. The TIMP level in the sera of 38 rheumatoid arthritis (RA) patients (241 +/- 53 ng/ml, mean +/- SD) was significantly higher (P less than 0.001) than the level in the sera of 81 healthy subjects (175 +/- 39). A similar significant difference (P less than 0.001) was observed between the TIMP level in platelet-poor plasma of normal subjects (64 +/- 10) and that of RA patients (84 +/- 23), suggesting that the increase in TIMP seen in RA sera can not be ascribed merely to an increase in platelet-derived TIMP. | |
| 3632317 | Atrophy of the thumb web space in rheumatoid arthritis: clinical and electrodiagnostic stu | 1987 | One hundred and twenty definite or classical rheumatoid arthritis (RA) patients with an average duration of the disease of 12.1 years were studied. Sixty-two patients had distinct atrophy of the first dorsal interosseous of the hand without definite signs of carpal, cubital, or ulnar tunnel syndrome (group A); 43 patients showed neither distinct atrophy nor sensory disturbance of either hand (group B). Other patients had sensory and/or motor disturbances due to carpal, cubital, or ulnar tunnel syndrome and other neuropathies. Electrodiagnostic examinations revealed that there were differences in the distal latency to the first dorsal interosseous muscle from the wrist between 24 group-A patients and 14 normal controls (P less than 0.05), and between the group-A patients and 12 group-B patients (P less than 0.1). The results of this study indicate that some RA patients with atrophy of the thumb web space may have compression neuropathy of the most distal branches of the ulnar nerve. | |
| 3070721 | IgG as antigen in human rheumatoid disease. | 1988 | Although the events underlying the expression of rheumatoid factor in patients with rheumatoid arthritis remain unknown, evidence from both human and animal studies has suggested a role for altered or complexed IgG. Similarly, altered or complexed IgG may also participate in initiating and sustaining inflammation in this disease. Potentially relevant differences in the glycosylation and conformation of rheumatoid IgG compared to IgG from healthy individuals have been detected by several investigators. The latter observations have raised new possibilities concerning mechanisms underlying the pathogenesis of rheumatoid arthritis and, in particular, the production of rheumatoid factor. | |
| 2124531 | Spontaneous and in vitro activation of synovial fluid and peripheral blood lymphocytes in | 1990 Sep | Peripheral blood (PB) and synovial fluid (SF) were compared in parallel samples in rheumatoid arthritis (RA). The kinetics of in vitro T-cell activation was assessed in phytohemagglutinin (PHA) stimulated PB or SF mononuclear cell cultures on days 0, 1, 3 and 5. The early lymphocyte activation as assessed by interleukin-2 receptor expression was faster in SF than in PB cell cultures. In particular, IFN-gamma secretion was higher in SF than in PB cell cultures (p less than 0.01). Accordingly, lymphocyte major histocompatibility complex (MHC) locus II antigen expression was higher in SF than in PB cell cultures (53 +/- 7% vs. 21 +/- 5%; p less than 0.01). Our results suggest that lymphocytes, which are particularly effective producers of IFN-gamma when stimulated in vitro are sequestered in the diseased joints in RA. | |
| 3743149 | Reappraisal of respiratory abnormalities in primary and secondary Sjögren's syndrome. A c | 1986 Sep | In order to appraise the significance of respiratory abnormalities in primary and secondary Sjogren's syndrome (pSS and sSS), we evaluated 40 patients with pSS, 26 with sSS, 40 with rheumatoid arthritis (RA) but no SS, and 100 age- and sex-matched control subjects. The most common functional abnormality was diffuse interstitial lung disease (DILD) in patients with pSS (37.5 percent) and obstructive ventilatory defect in RA and sSS patients (40 and 19 percent, respectively). DILD was also present in the last two groups (11.8 percent in sSS and 27.5 percent in RA), while obstructive defect was rare in pSS (2.5 percent). Abnormalities suggesting small airways disease were present in all patient groups and also in the control group with similar frequency. Patients with extraglandular pSS had most often DILD (52 percent). Patients with pSS and cryoglobulinemia had low C3 and C4 levels and decreased Dco, suggesting that interstitial lung disease may be a result of immune complex deposition. Clinical input of the functional abnormalities was minimal, expressed as dry cough and mild dyspnea. Pneumonia was not frequent, while pleurisy was present only in patients with sSS and RA. We suggest that, even though pulmonary abnormalities can frequently be detected with sensitive tests in patients with SS, they are not significant if compared with control subjects and are clinically negligible. | |
| 2969918 | Identification of a high-affinity receptor for interleukin 1 alpha and interleukin 1 beta | 1988 Aug | In this report the binding of recombinant human interleukins 1 alpha and 1 beta (rIL-1 alpha and rIL-1 beta) to primary cultures of human rheumatoid synovial cells is measured and compared to the concentrations of these mediators required for stimulation of PGE2 production by these same cells. The average concentration of IL-1 alpha required for half-maximal stimulation of PGE2 was 4.6 +/- 1.5 pM (+/- SEM) (n = 6), whereas for IL-1 beta half-maximal stimulation was observed at a concentration of 1.3 +/- 0.24 pM (n = 6). Both direct and competitive binding experiments were performed. In direct binding experiments, IL-1 alpha bound with a Kd of 66 pM (n = 1), while IL-1 beta bound with a Kd of 4 pM (n = 2). In competitive binding experiments, IL-1 alpha inhibited binding of 125I-IL-1 alpha with a Ki of 33-36 pM (n = 2) and binding of 125I-IL-1 beta with a Ki of 51-63 pM (n = 2). IL-1 beta inhibited binding of 125I-IL-1 alpha with a Ki of 2-3 pM (n = 2) and binding of 125I-IL-1 beta with a Ki of 7 pM (n = 2). The binding data were best fit by a model specifying a single class of receptors with homogeneous affinity for either IL-1 alpha or IL-1 beta and with an abundance of 3,000-14,000 sites per cell. Autoradiography showed that the vast majority of the synoviocytes within the cultures possessed IL-1 receptors. Comparison of biological response curves with the binding curves indicates that the observed receptors exhibit sufficiently high affinity to mediate the response of human synoviocytes to low picomolar concentrations of IL-1 alpha and IL-1 beta. | |
| 3052323 | Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid a | 1988 Sep | A patient is described with definite rheumatoid arthritis (RA) who developed life threatening acute pneumonitis after receiving a total dose of only 12.5 mg methotrexate (MTX). This complication has been previously described, but this is probably the lowest reported dose before development of pneumonitis in a patient with RA. The possible significance of this case is discussed in the light of recent reports suggesting an increased susceptibility of patients with RA to the pulmonary toxicity of MTX. | |
| 1856905 | Lung abscess caused by Rhodococcus equi. | 1991 Apr | In the immunocompromised patient, early diagnosis of a lung cavity is essential for appropriate treatment. Rhodococcus equi (formerly Corynebacterium equi) is a variably acid-fast bacterium that can produce cavitary disease in an immunocompromised host. The two cases presented here demonstrate the clinical and radiographic features of R equi lung abscess. The first patient was on long-term corticosteroid therapy for rheumatoid arthritis. The second patient had AIDS. The correct diagnosis in both cases was delayed because acid-fast bacilli seen on smears of sputum were presumed to be Mycobacterium tuberculosis. | |
| 2639236 | [Epidemiology of intra and extracapsular masticatory dysfunction in the period of growth]. | 1989 May | A clinical and epidemiological investigation was performed on 3 sample groups of adolescents with rheumatoid arthritis, vertebral scoliosis and recurring headaches in order to analyse the connections between their pathology and the signs and symptoms of mandibular dysfunction. The anamnestic and objective data were reviewed with the aid of the Helkimo indices and compared to data on a non-selected control group of comparable age. The most statistically significant signs encountered were point on impaired mandibular mobility and tenderness of the masticatory muscles. The high incidence of parafunctions indicated the behavioural substrate. This study underlines the need for early diagnosis, preventive identification of subjects at risk and interdisciplinary cooperation. | |
| 3392961 | Intraarticular injection of arthritogenic factor causes mast cell degranulation, inflammat | 1988 Jul | Arthritis resembling human rheumatoid arthritis is produced in rats either by immunization with type II collagen or injection of complete Freund's adjuvant. The development of arthritis in both models may be mediated by a T cell-derived, type II collagen-specific protein that has been termed arthritogenic factor. Here, the morphologic changes produced after intraarticular injection of this factor were determined. T cell lines were derived from type II collagen-immunized rats. Arthritogenic factor was isolated from culture supernatants by affinity chromatography on type II collagen-conjugated Sepharose and injected into rat knees. The synovium covering the infrapatellar fat pad was examined by light and electron microscopy at 6 hours to 7 days after injection. By 6 hours, the synovium and fat pad were edematous and heavily infiltrated with neutrophils and a few mononuclear cells. Fibrin was present in the synovium and joint space. Most mast cells had partially degranulated. By 24 hours, the infiltrate became primarily mononuclear and fewer neutrophils were seen. Fat necrosis and edema occurred in the subsynovium. By 48 hours and 7 days, the synovium was hyperplastic, some fibrin persisted, and macrophages were present. Control knees, injected with material obtained from T cell lines established with the antigen, ovalbumin, and subjected to type II collagen affinity chromatography, had less fibrin deposition, milder cellular infiltrates, and less mast cell degranulation than knees injected with arthritogenic factor. These studies suggest that arthritogenic factor stimulates acute cellular infiltration and mast cell secretion which is followed by fat necrosis, synovial hyperplasia, and mononuclear cell infiltration. | |
| 3704516 | [D-penicillamine in the treatment of rheumatoid polyarthritis. 104 cases with a 5-year fol | 1986 Jan | 104 patients with rheumatoid arthritis were treated by D-penicillamine and were followed for 5 years after the start of treatment. At the end of the 5th year, 27 patients (26 per cent) are still taking the treatment with satisfactory results; 47 patients (45 per cent) had to stop treatment because of intolerance; 15 patients (14.5 per cent) stopped treatment because of escape or because of a poor therapeutic result and 15 patients (14.5 per cent) could not be evaluated. In the patients treated for 5 years with a satisfactory result, there was a regular decrease in the articular index which was statistically significant during the first two years of treatment. The variations in the erythrocyte sedimentation rate were less spectacular: it only decreased significantly during the first year. The variations in the serum levels of rheumatoid factor were irregular. Systemic corticosteroid therapy was able to be stopped in 6 out of 7 cases. The authors did not observe any significant correlation between the results of treatment and the age of onset of the rheumatoid arthritis, the articular index, or the initial erythrocyte sedimentation rate. In contrast, the mean history of the disease was significantly shorter in the patients with a satisfactory result at the 5th year. The majority of suspensions of treatment took place during the first 2 years of treatment and were motivated by intolerance reactions, in particular renal intolerance. Whatever the reason for the suspension of treatment, it was not influenced by the history of the rheumatoid arthritis, the rheumatoid serology, the sex of the patient or the maximal dosage of D-penicillamine.(ABSTRACT TRUNCATED AT 250 WORDS) | |
| 2903927 | Comparison of responses to and adverse effects of graded doses of sulfasalazine in the tre | 1988 Sep | Sulfasalazine (0, 0.5, 1, or 2 g daily in divided doses) was given to patients with definite or classical rheumatoid arthritis (RA) insufficiently controlled by a nonsteroidal antiinflammatory drug. Grip strength, Westergren sedimentation rate, and physician and patient global assessment improved in those patients given 2 g/day. Inadequate response was the primary reason for withdrawal in the groups given placebo or 0.5 g/day, while adverse reactions (mainly gastrointestinal upset or rash) accounted for most withdrawals from the groups that received 1 or 2 g/day. Although its use is limited by adverse reactions, sulfasalazine is effective in the treatment of patients with RA. |